Zobrazeno 1 - 10
of 101
pro vyhledávání: '"James H, Flory"'
Autor:
Cheng Chen, Warren B Bilker, Charles E Leonard, Sean Hennessy, Colleen M Brensinger, James H Flory, Kacie Bogar, Christopher Shi
Publikováno v:
BMJ Open, Vol 14, Iss 10 (2024)
Objective Prior studies demonstrate that some untoward clinical outcomes vary by outdoor temperature. This is true of some endpoints common among persons with diabetes, a population vulnerable to climate change-associated health risks. Yet, prior wor
Externí odkaz:
https://doaj.org/article/6d48b05ad389429da02a6fb6a8763bf3
Autor:
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publikováno v:
Cancer Medicine, Vol 11, Iss 8, Pp 1796-1804 (2022)
Abstract Purpose The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several P
Externí odkaz:
https://doaj.org/article/6261ca0f91da4aafad9291fcc66547c9
Autor:
Chang Su, Yongkang Zhang, James H. Flory, Mark G. Weiner, Rainu Kaushal, Edward J. Schenck, Fei Wang
Publikováno v:
npj Digital Medicine, Vol 4, Iss 1, Pp 1-13 (2021)
Abstract The coronavirus disease 2019 (COVID-19) is heterogeneous and our understanding of the biological mechanisms of host response to the viral infection remains limited. Identification of meaningful clinical subphenotypes may benefit pathophysiol
Externí odkaz:
https://doaj.org/article/213f9521bb6142eebb7ea2c2c8bc56e2
Autor:
Charles E. Leonard, Colleen M. Brensinger, Ghadeer K. Dawwas, Rajat Deo, Warren B. Bilker, Samantha E. Soprano, Neil Dhopeshwarkar, James H. Flory, Zachary T. Bloomgarden, Joshua J. Gagne, Christina L. Aquilante, Stephen E. Kimmel, Sean Hennessy
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-11 (2020)
Abstract Background The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinedion
Externí odkaz:
https://doaj.org/article/7be6dabc839f4bdbb7f63feb7e38ed6d
Autor:
Tahj Blow BS, Parker N. Hyde PhD, John N. Falcone MD, Aaron Neinstein MD, Neil Vasan MD, PhD, Ritika Chitkara MPAS, Maurice A. Hurd BA, Sagar Sardesai MBBS, Maryam B. Lustberg MD, MPH, James H. Flory MD, MSCE, Jeff S. Volek PhD, Marcus D. Goncalves MD, PhD
Publikováno v:
Integrative Cancer Therapies, Vol 20 (2021)
Alpelisib is a α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treatment of postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–), PIK3CA-mutated, adv
Externí odkaz:
https://doaj.org/article/b81288c92b19435e8df3a6d05b91595f
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 3, Pp n/a-n/a (2021)
ABSTRACT Aims To compare rates of use and adherence for newer versus older second‐line diabetes drug classes in commercially insured, Medicare Advantage and dual‐eligible (covered by both Medicare and Medicaid) patients. Materials and Methods Lon
Externí odkaz:
https://doaj.org/article/717ddd14716d421094cbd9f0ced71b3e
Publikováno v:
British Journal of Surgery. 110:545-547
Autor:
JeaYoung Min, Will Simmons, Samprit Banerjee, Fei Wang, Nicholas Williams, Yongkang Zhang, April B. Reese, Alvin I. Mushlin, James H. Flory
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1402-1405
Autor:
Joel C, Cantor, Sujoy, Chakravarty, Jennifer, Farnham, Jose, Nova, Sana, Ahmad, James H, Flory
Publikováno v:
Medical Care. 60:481-487
Project ECHO (Extension for Community Healthcare Outcomes), a tele-mentoring program for health care providers, has been shown to improve provider-reported outcomes, but there is insufficient research on patient-level outcomes.To evaluate the impact
Publikováno v:
Diabetes Care
OBJECTIVE To assess the association of sodium–glucose cotransporter 2 (SGLT2) inhibitors with diabetic ketoacidosis compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas in patients with type 2 diabetes. RESEARCH DESIGN AND METH